Therapeutic Antibodies

Question 1

Alemtuzumab

Answer 1

CD52 CLL “Alymtuzumab”—chronic

lymphocytic leukemia

Question 2

Bevacizumab

Answer 2

VEGF Colorectal cancer, renal cell

carcinoma

Question 3

Cetuximab

Answer 3

EGFR Stage IV colorectal cancer,

head and neck cancer

Question 4

Rituximab

Answer 4

CD20 B-cell non-Hodgkin
lymphoma, rheumatoid
arthritis (with MTX), ITP

Question 5

Trastuzumab

Answer 5

HER2/neu Breast cancer, gastric cancer HER2—“tras2zumab”

Question 6

Infliximab,

adalimumab

Answer 6

TNF-α IBD, rheumatoid arthritis,
ankylosing spondylitis,
psoriasis
Rheumatoid arthritis “inflix”
pain in “da limbs”

Question 7

Natalizumab

Answer 7

α4-integrin Multiple sclerosis, Crohn
disease
α4-integrin: leukocyte
adhesion
Risk of PML in patients with
JC virus

Question 8

Abciximab

Answer 8

Glycoprotein IIb/IIIa Anti-platelet agent for
prevention of ischemic
complications in patients
undergoing percutaneous
coronary intervention
IIb times IIIa equals
“absiximab

Question 9

Denosumab

Answer 9

RANKL Osteoporosis; inhibits osteoclast
maturation (mimics
osteoprotegrin)
Denosumab affects osteoclasts

Question 10

Digoxin immune Fab

Answer 10

Digoxin Antidote for digoxin toxicity

Question 11

Omalizumab

Answer 11

IgE Allergic asthma; prevents IgE

binding to FceRI

Question 12

Palivizumab

Answer 12

RSV F protein RSV prophylaxis for high-risk
infants
PaliVIzumab—VIrus

Question 13

Vemurafenib MOA?

Answer 13

Small molecule inhibitor of BRAF oncogene ⊕ melanoma

Question 14

Trastuzumab (Herceptin) MOA?

Answer 14

Monoclonal antibody against HER-2 (c-erbB2), a tyrosine kinase receptor=> killing via ADCC

Question 15

Tamoxifen, raloxifene MOA?

Answer 15

Selective estrogen receptor modulators (SERMs)—receptor antagonists in breast and agonists in bone. Block the binding of estrogen to ER ⊕ cells.

Question 16

Erlotinib MOA?

Answer 16

EGFR tyrosine kinase inhibitor.